OBJECTIVE:To systematically evaluate the effects of atorvastatin on pulmonary function,pulmonary arterial pres-sure and related indexes in patients with stable chronic obstructive pulmonary disease(COPD),and to provide evidence-based refer-ence. METHODS:Retrieved from Cochrane Library,PubMed,EMBase,CJFD and VIP,randomized controlled trials(RCTs)about atorvastatin combined with conventional therapy(trial group)vs. conventional therapy alone(control group)in the treatment of sta-ble COPD were collected. Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation by Cochrane Handbook Manual 5.1.0. RESULTS:Totally 7 RCTs were included,involving 371 patients. Results of Me-ta-analysis showed,FEV1 [MD=0.07,95%CI(0.04,0.09),P<0.001],FEV1%pred [MD=6.18,95%CI(2.23,10.12),P=0.002] and 6MWD [MD=55.31,95%CI(36.44,74.18),P<0.001] of trial group were significantly higher/longer than those of con-trol group;pulmonary artery systolic pressure [MD=-6.78,95%CI(-11.62,-1.94),P=0.006],mean pulmonary artery pres-sure [MD=-6.61,95%CI(-7.26,-5.96),P<0.001],St. George respiratory questionnaire [MD=-13.21,95%CI(-23.90,-2.52), P=0.02] were significantly lower than control group,with statistical significance. There was no statistical difference in FEV1/FVC [MD=3.73,95%CI(-2.08,9.55),P=0.21] or hs-CRP [MD=0.29,95%CI(-1.37,1.95),P=0.73] between 2 groups. CONCLU-SIONS:Atorvastatin can significantly improve pulmonary function and pulmonary arterial pressure in patients with stable COPD, and can improve the quality of life.